CXCL16 and neoplasm: Comparative efficacy is therefore context-contingent: In LOX-high, stiff, hypoperfused niches, ECM normalization plus chemotherapy and/or ICB is rational; in glycolytic/CXCL16-rich niches, metabolic modulation plus chemotherapy and/or ICB is preferred; where stromal–tumor antigen co-expression is tumor-dominant, payload delivery is attractive; and in CAF-sparse settings (e.g., RMS), tumor-intrinsic targeting should predominate.